{"trials":[{"id":3607,"nct_id":"NCT07607938","title":"Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT07607938","tracker_url":"publication.php?id=3607","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-09","last_update_date":"2026-09-15","start_date":"2026-09","primary_completion_date":"2030-08-01","completion_date":"2030-09-30","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":90,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["Anhedonia","Emotional Blunting"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"facilities":[{"facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","key":"cc165a351c6fda51b401275218491287327386614c5e7a2bf2bf545f7bd501bb","mapped":true}],"selected_reports":[],"result_references":[],"results_posted":null,"result_references_checked":false,"countries":["United States"]},{"id":3587,"nct_id":"NCT06349083","title":"Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT06349083","tracker_url":"publication.php?id=3587","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-08","last_update_date":"2026-09-02","start_date":"2026-09-01","primary_completion_date":"2030-05","completion_date":"2030-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Alcohol Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Inactive Placebo","type":"OTHER"},{"name":"Supportive therapy sessions","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"facilities":[{"facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","key":"cc165a351c6fda51b401275218491287327386614c5e7a2bf2bf545f7bd501bb","mapped":true}],"selected_reports":[],"result_references":[],"results_posted":null,"result_references_checked":false,"countries":["United States"]},{"id":3598,"nct_id":"NCT06760533","title":"Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT06760533","tracker_url":"publication.php?id=3598","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-05","start_date":"2026-08","primary_completion_date":"2026-12","completion_date":"2026-12","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":10,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"TRIPLE"},"conditions":["IBS - Irritable Bowel Syndrome"],"interventions":[{"name":"Psilocybin 25 mg","type":"DRUG"},{"name":"Psychotherapy Treatment Session","type":"BEHAVIORAL"},{"name":"Niacin 100 mg","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"facilities":[{"facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","key":"cc165a351c6fda51b401275218491287327386614c5e7a2bf2bf545f7bd501bb","mapped":true}],"selected_reports":[],"result_references":[],"results_posted":null,"result_references_checked":false,"countries":["United States"]},{"id":3673,"nct_id":"NCT06796062","title":"A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT06796062","tracker_url":"publication.php?id=3673","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2026-01-23","start_date":"2025-12-17","primary_completion_date":"2029-02","completion_date":"2029-02","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":480,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Opioid Use Disorder"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"2efd177beb9722b60d05070a66389e71ae259668c4178f5411487061f62efb7c","facility":"Duke City Recovery Toolbox","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"8fccc71c53b40f7dc5e28040c7be06eae1a4b7bb5a7209d9aca29d9c5f6643d0","facility":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"cb49fa24dfbf8e250086b9d17c0538ca82fa2466c8dd249c6067d4280ab1f354","facility":"StartCare","city":"Brooklyn","region":"New York","country":"United States","lat":40.650100000000002,"lon":-73.949579999999997},{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"cbc94afe933fcad9921964a6f0b6402d02a73d8e689068a95ac7f922a80f8c1f","facility":"VIP Community Services, Inc","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002}],"facilities":[{"facility":"Duke City Recovery Toolbox","city":"Albuquerque","region":"New Mexico","country":"United States","key":"09f5b5ec96d2a3c5a4d4d12c21f811e4050fcb748133806c58f0a0b85fafd6ec","mapped":true},{"facility":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","key":"fa4cb7557936a9b1549e9428982be10c275c523ad962f367473155565bfbad2c","mapped":true},{"facility":"StartCare","city":"Brooklyn","region":"New York","country":"United States","key":"4927aac83cd67ce4dbd1071f616f0e98789ad05de5013740397ca980912a4bad","mapped":true},{"facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","key":"cc165a351c6fda51b401275218491287327386614c5e7a2bf2bf545f7bd501bb","mapped":true},{"facility":"VIP Community Services, Inc","city":"The Bronx","region":"New York","country":"United States","key":"1b3bb4864ab85dfdc790184fa7fcdc06266c67e6d13b86cbddd6327f82051743","mapped":true}],"selected_reports":[],"result_references":[],"results_posted":null,"result_references_checked":false,"countries":["United States"]},{"id":3585,"nct_id":"NCT07296328","title":"Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT07296328","tracker_url":"publication.php?id=3585","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2025-12","last_update_date":"2025-12-22","start_date":"2026-01-15","primary_completion_date":"2027-04-01","completion_date":"2027-04-01","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":25,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Stuttering"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Speech therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"facilities":[{"facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","key":"cc165a351c6fda51b401275218491287327386614c5e7a2bf2bf545f7bd501bb","mapped":true}],"selected_reports":[],"result_references":[],"results_posted":null,"result_references_checked":false,"countries":["United States"]},{"id":3513,"nct_id":"NCT05398484","title":"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT05398484","tracker_url":"publication.php?id=3513","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-12","last_update_date":"2025-12-04","start_date":"2023-05-24","primary_completion_date":"2027-01-01","completion_date":"2027-01-01","study_type":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"enrollment":{"count":200,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"DOUBLE"},"conditions":["Advanced Cancer"],"interventions":[{"name":"Psilocybin 25 mgs","type":"DRUG"},{"name":"Niacin 100mg","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"7af9ac6392b1552d76cfb9c7864f12f879094bf439d72053786dd890245b723b","facility":"University of Colorado Anschutz Medical campus (CU AMC)","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"facilities":[{"facility":"University of Colorado Anschutz Medical campus (CU AMC)","city":"Aurora","region":"Colorado","country":"United States","key":"073b5ac95dd871ded46e5592aeb7f0a57192ad06077c111af2c540b8d1d915d1","mapped":true},{"facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","key":"cc165a351c6fda51b401275218491287327386614c5e7a2bf2bf545f7bd501bb","mapped":true}],"selected_reports":[],"result_references":[],"results_posted":null,"result_references_checked":false,"countries":["United States"]},{"id":3442,"nct_id":"NCT02061293","title":"A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT02061293","tracker_url":"publication.php?id=3442","status":"COMPLETED","status_label":"Completed","status_verified_date":"2022-10","last_update_date":"2022-11-08","start_date":"2014-06","primary_completion_date":"2021-07-30","completion_date":"2021-07-30","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":95,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Alcohol Dependence"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Diphenhydramine","type":"DRUG"},{"name":"Motivational Enhancement and Taking Action (META)","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"d761fe5f7a78138ff98cd1bb8712803a88c9a303339158053d3bf4cc3260d670","facility":"University of New Mexico Health Sciences Center","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"2715c70c5a3cf61074816c8f4c0e3981b0c63530ec8157146313a3c8963e5794","facility":"Clinical and Translational Science Institute, NYU Langone Medical Center","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"facilities":[{"facility":"University of New Mexico Health Sciences Center","city":"Albuquerque","region":"New Mexico","country":"United States","key":"47ce6fc3fd404b267109ab097dab068fd1b21c881fc52307731c7b9549b5904f","mapped":true},{"facility":"Clinical and Translational Science Institute, NYU Langone Medical Center","city":"New York","region":"New York","country":"United States","key":"a53d7d38ddf9246ac3f40e523513b6545050e5ce310095f34f21b0d31efefb2b","mapped":true}],"selected_reports":[{"label":"Bogenschutz et al. · 2022","url":"https://doi.org/10.1001/jamapsychiatry.2022.2096","paper_id":1681,"basis":"Selected source-checked evidence guide"}],"result_references":[],"results_posted":null,"result_references_checked":false,"countries":["United States"]},{"id":3508,"nct_id":"NCT02421263","title":"A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT02421263","tracker_url":"publication.php?id=3508","status":"COMPLETED","status_label":"Completed","status_verified_date":"2022-02","last_update_date":"2022-02-14","start_date":"2015-04","primary_completion_date":"2020-06-05","completion_date":"2020-06-05","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":12,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"HEALTH_SERVICES_RESEARCH","masking":"NONE"},"conditions":["Religious or Spiritual Problem"],"interventions":[{"name":"Psilocybin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"d1d8d084525b2d3486bf0c2b7d493ab1c682a967c30c20c77a945624472cd2ab","facility":"NYU Langone Medical Center/Tisch Hospital","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"facilities":[{"facility":"NYU Langone Medical Center/Tisch Hospital","city":"New York","region":"New York","country":"United States","key":"59c284798afcf9adb3aea682af2e2bb3c75bff9197c8315cc731d44d46bde1a0","mapped":true}],"selected_reports":[],"result_references":[],"results_posted":null,"result_references_checked":false,"countries":["United States"]},{"id":3429,"nct_id":"NCT00957359","title":"Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients","sponsor":"NYU Langone Health","registry_url":"https://clinicaltrials.gov/study/NCT00957359","tracker_url":"publication.php?id=3429","status":"COMPLETED","status_label":"Completed","status_verified_date":"2020-09","last_update_date":"2020-10-20","start_date":"2009-02","primary_completion_date":"2018-09-06","completion_date":"2018-09-06","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":29,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"CROSSOVER","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Cancer"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Niacin","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"78b406395b11d45e5de52f1bd4997ed2ba1a3a3edbf561ff0ce4bc7bc43bb19f","facility":"NYU College of Dentistry Bluestone Center for Clinical Research","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"facilities":[{"facility":"NYU College of Dentistry Bluestone Center for Clinical Research","city":"New York","region":"New York","country":"United States","key":"c10cf7d345baf62ac023a98ed014774ef118d6f531ad21d1775fc3d221c15f44","mapped":true}],"selected_reports":[],"result_references":[],"results_posted":null,"result_references_checked":false,"countries":["United States"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2009":1,"2014":1,"2015":1,"2023":1,"2025":1,"2026":4},"statuses":{"Recruiting":4,"Completed":3,"Not yet recruiting":2},"conditions":{"Anhedonia":1,"Emotional Blunting":1,"Alcohol Use Disorder":1,"IBS - Irritable Bowel Syndrome":1,"Opioid Use Disorder":1,"Stuttering":1,"Advanced Cancer":1,"Alcohol Dependence":1,"Religious or Spiritual Problem":1,"Cancer":1},"sites":[{"key":"f013c15d8112693910d9bf055f39dc54c2a9c3749b21ac7dacc4c09c7de423df","facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"2efd177beb9722b60d05070a66389e71ae259668c4178f5411487061f62efb7c","facility":"Duke City Recovery Toolbox","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"8fccc71c53b40f7dc5e28040c7be06eae1a4b7bb5a7209d9aca29d9c5f6643d0","facility":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"cb49fa24dfbf8e250086b9d17c0538ca82fa2466c8dd249c6067d4280ab1f354","facility":"StartCare","city":"Brooklyn","region":"New York","country":"United States","lat":40.650100000000002,"lon":-73.949579999999997},{"key":"cbc94afe933fcad9921964a6f0b6402d02a73d8e689068a95ac7f922a80f8c1f","facility":"VIP Community Services, Inc","city":"The Bronx","region":"New York","country":"United States","lat":40.849850000000004,"lon":-73.866410000000002},{"key":"7af9ac6392b1552d76cfb9c7864f12f879094bf439d72053786dd890245b723b","facility":"University of Colorado Anschutz Medical campus (CU AMC)","city":"Aurora","region":"Colorado","country":"United States","lat":39.729430000000001,"lon":-104.83192},{"key":"d761fe5f7a78138ff98cd1bb8712803a88c9a303339158053d3bf4cc3260d670","facility":"University of New Mexico Health Sciences Center","city":"Albuquerque","region":"New Mexico","country":"United States","lat":35.084490000000002,"lon":-106.65114},{"key":"2715c70c5a3cf61074816c8f4c0e3981b0c63530ec8157146313a3c8963e5794","facility":"Clinical and Translational Science Institute, NYU Langone Medical Center","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"d1d8d084525b2d3486bf0c2b7d493ab1c682a967c30c20c77a945624472cd2ab","facility":"NYU Langone Medical Center/Tisch Hospital","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005},{"key":"78b406395b11d45e5de52f1bd4997ed2ba1a3a3edbf561ff0ce4bc7bc43bb19f","facility":"NYU College of Dentistry Bluestone Center for Clinical Research","city":"New York","region":"New York","country":"United States","lat":40.714269999999999,"lon":-74.005970000000005}],"facilities":[{"facility":"Clinical and Translational Science Institute, NYU Langone Medical Center","city":"New York","region":"New York","country":"United States","key":"a53d7d38ddf9246ac3f40e523513b6545050e5ce310095f34f21b0d31efefb2b","mapped":true},{"facility":"Duke City Recovery Toolbox","city":"Albuquerque","region":"New Mexico","country":"United States","key":"09f5b5ec96d2a3c5a4d4d12c21f811e4050fcb748133806c58f0a0b85fafd6ec","mapped":true},{"facility":"NYU College of Dentistry Bluestone Center for Clinical Research","city":"New York","region":"New York","country":"United States","key":"c10cf7d345baf62ac023a98ed014774ef118d6f531ad21d1775fc3d221c15f44","mapped":true},{"facility":"NYU Langone Health","city":"New York","region":"New York","country":"United States","key":"cc165a351c6fda51b401275218491287327386614c5e7a2bf2bf545f7bd501bb","mapped":true},{"facility":"NYU Langone Medical Center/Tisch Hospital","city":"New York","region":"New York","country":"United States","key":"59c284798afcf9adb3aea682af2e2bb3c75bff9197c8315cc731d44d46bde1a0","mapped":true},{"facility":"StartCare","city":"Brooklyn","region":"New York","country":"United States","key":"4927aac83cd67ce4dbd1071f616f0e98789ad05de5013740397ca980912a4bad","mapped":true},{"facility":"University of Colorado Anschutz Medical campus (CU AMC)","city":"Aurora","region":"Colorado","country":"United States","key":"073b5ac95dd871ded46e5592aeb7f0a57192ad06077c111af2c540b8d1d915d1","mapped":true},{"facility":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","key":"fa4cb7557936a9b1549e9428982be10c275c523ad962f367473155565bfbad2c","mapped":true},{"facility":"University of New Mexico Health Sciences Center","city":"Albuquerque","region":"New Mexico","country":"United States","key":"47ce6fc3fd404b267109ab097dab068fd1b21c881fc52307731c7b9549b5904f","mapped":true},{"facility":"VIP Community Services, Inc","city":"The Bronx","region":"New York","country":"United States","key":"1b3bb4864ab85dfdc790184fa7fcdc06266c67e6d13b86cbddd6327f82051743","mapped":true}],"enrollment":{"sum":1141,"known_trials":9},"registry_checked_at_utc":"2026-10-09 01:24:43"}